Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma (Q38394496)

2 September 2017

1 reference

title

Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma (English)

1 reference

2 September 2017

Andrea Ladányi

1 reference

2 September 2017

language of work or name

1 reference

26 March 2015

1 reference

Pigment Cell & Melanoma Research

2 September 2017

published in

1 reference

2 September 2017

1 reference

2 September 2017

1 reference

2 September 2017

page(s)

490-500

1 reference

The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Model predicting survival in stage I melanoma based on tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Naturally occurring B-cell responses to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Close encounters of different kinds: dendritic cells and NK cells take centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Monocyte/macrophage infiltration in tumors: modulators of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Correlation among metallothionein expression, intratumoural macrophage infiltration and the risk of metastasis in human cutaneous malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

The plasmacytoid monocyte/interferon producing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

The significant role of mast cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

CD4 regulatory T cells in human cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Ectopic lymphoid structures in primary cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Immunological monitoring of the tumor immunoenvironment for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

CD20+ B cells: the other tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

On the dual roles and polarized phenotypes of neutrophils in tumor development and progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

B cells inhibit induction of T cell-dependent tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Immune cells and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Mast cells, angiogenesis, and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Mast cells in melanocytic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

New aspects of natural-killer-cell surveillance and therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Inflammation-mediated promotion of invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Understanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

The anticancer immune response: indispensable for therapeutic success?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Immune parameters affecting the efficacy of chemotherapeutic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I–II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

An immune-active tumor microenvironment favors clinical response to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

Dacarbazine Promotes Stromal Remodeling and Lymphocyte Infiltration in Cutaneous Melanoma Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12371

21 January 2018

Identifiers

DOI

10.1111/PCMR.12371

1 reference

release_liiy2w3bmzc3daptexz2s462j4

2 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/liiy2w3bmzc3daptexz2s462j4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference